Dudediligence.

Beam Therapeutics Inc

BEAMNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$14.3MSep ’24$30.1MDec ’24$7.5MMar ’25$8.5MJun ’25$9.7MSep ’25$114.1MDec ’25$31.7MMar ’26$490,000Jun ’26
Net income, by quarter
−$96.7MSep ’24−$90.4MDec ’24−$108.3MMar ’25−$102.3MJun ’25−$112.7MSep ’25$244.3MDec ’25−$94.3MMar ’26−$122.7MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$51.8M$60.9M$377.7M$63.5M$139.7M
Operating income−$392.5M−$338.5M−$176.5M−$415.6M−$383.7M
Net income−$370.6M−$289.1M−$132.5M−$376.7M−$80.0M
Operating cash flow−$66.3M$22.5M−$149.2M−$347.2M−$345.1M
Free cash flow−$113.1M−$26.4M−$182.9M−$356.2M−$360.0M
Cash$560.0M$232.8M$435.9M$282.0M$294.9M
Shares outstanding68.4M71.3M81.6M83.6M101.7M